logo
China's EV Makers Are Facing a Reality Check in Southeast Asia

China's EV Makers Are Facing a Reality Check in Southeast Asia

Bloomberg02-03-2025

On a recent Thursday morning in Hanoi, Chinese electric vehicle giant BYD Co. began the day with a showroom devoid of customers. Just a few kilometers away, a dealership for upstart Vietnamese EV maker VinFast Auto Ltd. was buzzing, with would-be buyers pouring over new models.
'We see an average of 20 customers every day during weekdays,' said Tran Trung Hieu, a VinFast salesman in black suit and tie. 'That can double or triple on a weekend.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Rosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation
Rosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation

Business Wire

timean hour ago

  • Business Wire

Rosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public. So What: If you purchased GeneDx securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. What to do next: To join the prospective class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@ for information on the class action. What is this about: On February 5, 2025, Grizzly Research published a report entitled 'Insiders Attest that GeneDx (Nasdaq: WGS) Is Actively Committing Widespread Fraud.' This report stated that Grizzly believed that GeneDx's 'growth is largely an illusion, driven by fraudulent schemes and illegal tactics deliberately aimed at exploiting Medicaid and Medicare systems to artificially inflate revenue.' On this news, GeneDx stock fell 6.7% on February 5, 2025. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time, Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone, the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by Law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.

UBS likes these defensive plays – which also happen to offer solid dividends
UBS likes these defensive plays – which also happen to offer solid dividends

CNBC

timean hour ago

  • CNBC

UBS likes these defensive plays – which also happen to offer solid dividends

The S & P 500 has made a stunning comeback from its lows in April, but UBS said investors would be wise to add some defensive stocks to their portfolios to guard against uncertainty. In a June 6 report, UBS global equity strategist Andrew Garthwaite gave several reasons why his team is cautious on many cyclical names – that is, stocks whose performance is closely tied to the economic cycle – excluding financials. "UBS forecasts US GDP to slow (from 2.1% YoY in Q1 to 0.9% in Q4), soft data has weakened sharply in the US – much more than hard data, which is now turning down – and UBS recession indicators show overall recession probability has ticked up to 37% in the next 12 months," he wrote. Even as stocks have made a strong recovery since the Trump administration announced a raft of tariffs in April, plenty of hurdles remain. For starters, the U.S. budget deficit ballooned to $316 billion in May , bringing the year-to-date total to $1.36 trillion. Further, U.S. and Chinese officials are awaiting approval of a trade policy framework. And the Federal Reserve's next steps on interest rate policy are still up in the air. That's where defensive plays come in. Garthwaite noted that cyclicals are looking expensive compared to defensive names on a price-to-earnings and price-to-book basis. He and his team plucked a few buy-rated names within the S & P 500 that could be worth consideration. "On the defensive side, we focus on names without high leverage (to avoid the risk of higher bond yields)," said Garthwaite. To top that off, several of the names also pay dividends, which can help cushion investors' portfolios from market jolts. Johnson & Johnson One of the names Garthwaite's team highlighted include Johnson & Johnson . Shares are up more than 7% in 2025, and the stock pays a dividend yield of about 3.4%. Analysts largely deem the stock a hold, seeing more than 9% upside from current levels, according to LSEG. Last month, Goldman Sachs lifted its price target on the pharmaceutical giant to $176 from $172, placing Johnson & Johnson on its conviction list. "JNJ is a stable, defensive grower with the industry's strongest balance sheet allowing for continued high [return on invested capital] investments in the Innovative Medicines segment to augment revenue growth," Goldman said in a May report. The firm noted that Johnson & Johnson "has a strong pipeline," including "meaningful revenue opportunities" in medications to treat multiple myeloma, lung cancer and other maladies. PepsiCo The snacking and soda giant made it to UBS's list as a buy-worthy defensive play. Shares have slid nearly 15% in 2025, and the stock pays a dividend yield of 4.4%. Analysts largely rate PepsiCo a hold, but consensus price targets call for almost 15% upside from where the Frito-Lay parent currently trades, according to LSEG. In May, the company raised its quarterly dividend to $1.4225 per share, a 5% increase from the year-ago period. The company has been paying steady dividends since 1965, and this year marked its 53rd consecutive annual dividend increase. PepsiCo has also been growing its product line lately. Last month, the Gatorade maker completed its acquisition of probiotic soda brand Poppi for $1.95 billion, including $300 million of anticipated cash tax benefits . Other buy-rated dividend payers on UBS's list included Merck , Elevance Health and Cigna .

Nvidia will stop including China in its forecasts amid US chip export controls, CEO says
Nvidia will stop including China in its forecasts amid US chip export controls, CEO says

CNN

timean hour ago

  • CNN

Nvidia will stop including China in its forecasts amid US chip export controls, CEO says

Chipmaker Nvidia will exclude the Chinese market from its revenue and profit forecasts following the imposition of tough US restrictions on chip sales to China, its CEO said Thursday. Asked whether the US will lift export controls after trade talks with China in London this week, Nvidia CEO Jensen Huang told CNN's Anna Stewart in Paris: 'I'm not counting on it but, if it happens, then it will be a great bonus. I've told all of our investors and shareholders that, going forward, our forecasts will not include the China market.' In recent years, Washington has stepped up efforts to restrict China's access to American chip-related technologies, aiming to prevent Beijing from using US innovations to bolster its military and artificial intelligence capabilities. Huang's comments underscore the impact of Washington's chip curbs on Nvidia, a company once best known for its video game graphics processors, that has profited tremendously from growing demand for AI chips and infrastructure. The company blew past Wall Street's revenue expectations in its first quarter of 2025, posting a 69% increase from the same period last year. But Nvidia missed out on an additional $2.5 billion in revenue because export restrictions prevented it from shipping its H20 AI chips to China. The company developed that chip specifically to accommodate US export controls but was told in April that it would need a special license to do so. Nvidia took a smaller hit than expected from the excess inventory, however: a $4.5 billion charge compared to the $5.5 billion it had expected. Kevin Hassett, director of the US National Economic Council, told CNBC Monday that the Trump administration might be open to loosening restrictions on exports of some microchips that China views as critical to its manufacturing sector. But the United States will maintain curbs on 'very, very high-end Nvidia' chips that are capable of powering AI systems, he added. On Thursday, Nvidia's Huang again criticized US chip export controls. 'The goals of the export controls are not being achieved,' he told CNN. 'Whatever those goals are that were being discussed initially, (they) are apparently not working. And so I think, with all export controls, the goals have to be well-articulated and tested over time.' Last month, Huang said at a news conference in Taiwan that the US curbs on chip exports were a 'failure' and warned that the restrictions were doing more damage to American business than to China. Nvidia's position as a critical supplier of AI chips has put it in the middle of the tech race between the US and China, which escalated earlier this year with the arrival of Chinese tech startup DeepSeek's supposedly cheap yet sophisticated AI model. The Trump administration has been eager to position the US as a leader in AI, with Vice President JD Vance saying that 'excessive regulation of the AI sector' could 'kill a transformative industry just as it's taking off' during remarks at the Artificial Intelligence Action Summit in Paris earlier this year. Dan Ives, global head of technology research at Wedbush Securities, said easing export controls could be necessary to prevent China from gaining an edge in AI. 'With the AI Revolution hitting its next gear of growth it is important for China tech players they get access to Nvidia chips with the current H20 ban essentially handing a good portion of Nvidia's business directly to Huawei on a silver platter,' he wrote in a June 11 industry note. In the meantime, Nvidia continues to expand – aiming to cement its place as a major AI player globally. Huang announced on Thursday that his company will build the world's first cloud computing platform for industrial artificial intelligence applications in Europe. It also said its Blackwell architecture will power new AI infrastructure projects in Europe. Olesya Dmitracova and Clare Duffy contributed to this article.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store